Oppenheimer analyst Mohan Naidu views the sell-off in Evolent Health (NYSE: EVH) is overdone and overshadows upcoming opportunities. The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE